Alder BioPharmaceuticals Inc. announced positive results from its late-stage migraine drug trial, keeping the company on track to potentially apply for Food and Drug Administration approval next year.
While Alder met it’s primary and secondary endpoints for the Promise 1 trial, the results weren’t much better than the placebo.
Patients treated with Alder’s Eptinezumab drug had on average 4.3 fewer migraine days per month on a high dose and 3.9 fewer days per month on a low dose, compared…
Alder BioPharmaceuticals Inc. announced positive results from its late-stage migraine drug trial, keeping the company on track to potentially apply for Food and Drug Administration approval next year.
While Alder met it’s primary and secondary endpoints for the Promise 1 trial, the results weren’t much better than the placebo.
Patients treated with Alder’s Eptinezumab drug had on average 4.3 fewer migraine days per month on a high dose and 3.9 fewer days per month on a low dose, compared…